FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal

After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major beneficiary” of this program, according to analysts at William Blair.